

# COEGIN

PHARMA

Lars Bukhave Rasmussen  
CFO

# Disclaimer

This presentation has been prepared by Coegin Pharma AB solely for information purposes. The presentation contains statements about the future and assumptions about future market conditions, operations, market shares, sales, earnings and milestones. The words "consider", "intend", "estimate", "expect", "predict", "plan", "project" or other related words indicate some of these statements about the future. Other statements can be identified by the context. Actual occurrences including financial performance measures can differ from the statements about the future given in this presentation, as a result of risks or other factors that Coegin Pharma AB or its subsidiaries are affected by. Market data and industry information used throughout this presentation are based on management's knowledge of the industry and the good faith estimates of management. We also relied, to the extent available, upon management's review of independent industry surveys and publications and other publicly available information prepared by a number of third-party sources. All of the market data and industry information used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Although we believe that these sources are reliable, we cannot guarantee the accuracy or completeness of this information, and we have not independently verified this information. While we believe the estimated market position, market opportunity and market size information included in this presentation are generally reliable, such information, which is derived in part from management's estimates and beliefs, is inherently uncertain and imprecise. Projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in our estimates and beliefs and in the estimates prepared by independent parties. Product research and development is inherently risky, and there is always a chance of partial or complete failure. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares or other securities in the company and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing, or selling of shares or other securities in the company and does not take into account any investor's particular objectives, financial situation or needs. The communication in this presentation may be restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation.

# Coegin Pharma AB

Swedish biotech company based in Lund

Home to both early and late-stage pipeline projects, across multiple technology platforms, within hair growth stimulation, myocardial infarction, leukemia, and skin cancers


First-in-class projects (no me-too / re-formulation projects)


Pharma and consumer care experienced management team

Publically listed at NGM Nordic SME


Shares can be traded e.g. via Nordnet

Dual listing on Börse Stuttgart ongoing





**Jens Eriksson**  
CEO



**John Zibert**  
CMO

## Dermacosmetic products



**Hair growth**  
FOL005

Research

Development

Registration



## Drug projects



**Myocardial infarction**  
FOL026



**Leukemia**  
AVX420



**Actinic keratosis**  
AVX001



**Basal cell carcinoma**  
AVX001

Research

Preclinical

Phase 1

Phase 2a

Phase 2b



## Dermacosmetic products



Hair growth  
FOL005

Research

Development

Registration





8+ billionEUR

- Global hair loss treatment market

# Hairloss is a major problem

- Affecting more than 50% of the world population

## No stellar options currently or upcoming:

- **Drugs:** Minoxidil and finasterid
- **Cosmetics:** Various synthetic and natural ingredients
- **Procedures:** Transplantation, light-, and platelet rich plasma treatments



# FOL005, Coegin Pharma's proprietary peptide

- A modified version of osteopontins active site




Osteopontin is a human protein playing a key role in sustaining healthy hair growth



# FOL005 product(s)

- Once daily hair growth stimulation



**FOL005: HAIR GROWTH**



# Five clinical studies successfully completed

- Including >300 people



## First in Man trial FCS-001

10 male subjects completed the single ascending intra dermal dose  
33 male subjects completed the multiple intra dermal dose part, 12 weeks treatment



## Phase II trial FCS-002

60 males diagnosed with androgenetic alopecia, treated with multiple intra dermal doses for 3 months  
53 completed 12 weeks of treatment



## Phase IIa trial FCS-003

210 males with androgenetic alopecia, treated topically with vehicle, FOL005 0.1%, 0.5%, or 1.5%  
199 completed 16 weeks of treatment



## Cosmetic 48 hour patch tests for acute skin irritation (primary irritation)

12 males and women with sensitive or normal skin treated topically with vehicle or FOL005 1.5%  
12 completed 1 week of treatment



## Cosmetic Human Repeat Insult Patch Testing (HRIPT)

52 males and women with sensitive or normal skin treated topically with vehicle or FOL005 1.5%  
52 completed 9 applications for 3 weeks,  
followed by a two-week rest period, after which the skin was exposed again


**FOL005: HAIR GROWTH**



# Significant effect already after 4 month

- Dose dependant efficacy, no safety concerns

Data from phase IIa trial (FCS-003)




# Results close up

- Phase IIa trial (FCS-003)


Day 0

Day 112 (16 weeks)

1.5%



0.5%



**FOL005: HAIR GROWTH**

# Unique product profile

**Clinically proven safety and efficacy incl. high responder rates (+70%)**  
Clear differentiator vs. other cosmetics and drugs

**Once daily application**  
Clear differentiator vs. other cosmetic products and minoxidil

**Suitable for both for males and females, without a prescription**  
Clear differentiator vs. finasteride

**Individual strengths, formulation and packaging opportunities**  
for male/female, scalp / eye lashes / beard, initiation/maintenance

**Premium cosmetic price ("selling") point (50-150 EUR/month)**  
Clear advantage vs. drugs

# Scalp hair – Women



**FOL005: HAIR GROWTH**



Draft product mock-up's only – Final presentations still under development



# Eyebrows



FOL005: HAIR GROWTH



Draft product mock-up's only – Final presentations still under development

# Eyelashes



FOL005: HAIR GROWTH



Draft product mock-up's only – Final presentations still under development

# Scalp hair - Men



**FOL005: HAIR GROWTH**



Draft product mock-up's only – Final presentations still under development

# Beard



FOL005: HAIR GROWTH



Draft product mock-up's only - Final presentations still under development

# Milestone plan

**2024** Licence agreement with commercial partners  
Finalise the final cosmetic safety testings and key market registrations

**2025** Production scale-up finalised  
Product launch in initial markets



**2026** Product launch in follow-on markets



## Dermacosmetic products



**Hair growth**  
FOL005

Research

Development

Registration



## Drug projects



**Myocardial infarction**  
FOL026



**Leukemia**  
AVX420



**Actinic keratosis**  
AVX001



**Basal cell carcinoma**  
AVX001

Research

Preclinical

Phase 1

Phase 2a

Phase 2b



# Coegin Pharma AB

Swedish biotech company based in Lund

Home to both early and late-stage pipeline projects, across multiple technology platforms, within hair growth stimulation, myocardial infarction, leukemia, and skin cancers


First-in-class projects (no me-too / re-formulation projects)

Pharma and consumer care experienced management team

Publically listed at NGM Nordic SME



The shares can be traded e.g. via Nordnet

Dual listing on Börse Stuttgart ongoing





[www.coeginpharma.com](http://www.coeginpharma.com)



**COEGIN**  
PHARMA